â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•—
â•‘                      VIRO-AI PREDICTIVE ANALYSIS                       â•‘
â•‘                 Comprehensive Viral Threat Assessment                  â•‘
â•šâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ [1] MUTATION PREDICTION                                                â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Current Virus: SARS-CoV-2 (Omicron BA.5)                              â”‚
â”‚ Analyzed Sequences: 1,000 samples                                      â”‚
â”‚                                                                         â”‚
â”‚ PREDICTED NEXT MUTATION: BA.5.2.1 (Q493R + F486V)                     â”‚
â”‚ Mutation Confidence: 87%                                                â”‚
â”‚ Estimated Timeline: 3-6 months                                         â”‚
â”‚                                                                         â”‚
â”‚ Key Mutations Detected:                                                â”‚
â”‚   â€¢ Q493R (Glutamine â†’ Arginine) - Spike RBD                          â”‚
â”‚   â€¢ F486V (Phenylalanine â†’ Valine) - Antibody escape                  â”‚
â”‚   â€¢ L452R (Leucine â†’ Arginine) - Immune evasion                       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ [2] DEADLINESS SCORE ANALYSIS                            âš ï¸ CRITICAL    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                         â”‚
â”‚     DEADLINESS SCORE: 76 / 100                                         â”‚
â”‚     â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘â–‘â–‘â–‘                          â”‚
â”‚                                                                         â”‚
â”‚ Risk Classification: HIGH RISK (Score 70-85)                           â”‚
â”‚                                                                         â”‚
â”‚ Score Breakdown:                                                        â”‚
â”‚   â€¢ Transmissibility:      â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘ 82/100  (High)                  â”‚
â”‚   â€¢ Immune Evasion:        â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘ 78/100  (High)                  â”‚
â”‚   â€¢ Mortality Rate:        â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘â–‘â–‘ 65/100  (Medium-High)           â”‚
â”‚   â€¢ Infection Severity:    â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘â–‘ 74/100  (High)                  â”‚
â”‚   â€¢ Vaccine Resistance:    â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘ 81/100  (High)                  â”‚
â”‚                                                                         â”‚
â”‚ Historical Comparison:                                                  â”‚
â”‚   â€¢ Original SARS-CoV-2: 62/100                                        â”‚
â”‚   â€¢ Delta Variant: 71/100                                              â”‚
â”‚   â€¢ Omicron BA.5: 68/100                                               â”‚
â”‚   â€¢ Predicted BA.5.2.1: 76/100 âš ï¸ INCREASED                            â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ [3] PREDICTED CLINICAL SYMPTOMS                                        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Based on mutation profile and deadliness score analysis:              â”‚
â”‚                                                                         â”‚
â”‚ PRIMARY SYMPTOMS (Probability):                                        â”‚
â”‚   ğŸ”´ Severe Respiratory Distress  (87%)                                â”‚
â”‚   ğŸ”´ High Fever (>39Â°C)            (92%)                                â”‚
â”‚   ğŸŸ¡ Persistent Cough              (85%)                                â”‚
â”‚   ğŸŸ¡ Fatigue & Weakness            (78%)                                â”‚
â”‚   ğŸŸ¡ Shortness of Breath           (81%)                                â”‚
â”‚                                                                         â”‚
â”‚ SECONDARY SYMPTOMS:                                                    â”‚
â”‚   â€¢ Loss of taste/smell (62%)                                          â”‚
â”‚   â€¢ Muscle aches (71%)                                                 â”‚
â”‚   â€¢ Headache (68%)                                                     â”‚
â”‚   â€¢ Gastrointestinal issues (45%)                                      â”‚
â”‚                                                                         â”‚
â”‚ SEVERE COMPLICATIONS (Estimated):                                      â”‚
â”‚   âš ï¸ Pneumonia risk: 34% (up from 28% in BA.5)                        â”‚
â”‚   âš ï¸ Hospitalization rate: 18-22%                                      â”‚
â”‚   âš ï¸ ICU admission: 6-8%                                               â”‚
â”‚                                                                         â”‚
â”‚ AFFECTED ORGANS/SYSTEMS:                                               â”‚
â”‚   ğŸ”´ Respiratory System (Primary target)                               â”‚
â”‚   ğŸŸ¡ Cardiovascular System (Secondary)                                 â”‚
â”‚   ğŸŸ¡ Immune System (Dysregulation)                                     â”‚
â”‚   ğŸŸ¢ Neurological (Mild impact)                                        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ [4] TOP DRUG CANDIDATES - RANKED BY BINDING AFFINITY                  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                         â”‚
â”‚ #1 BEST CANDIDATE: Nirmatrelvir (Paxlovid)               â­ OPTIMAL   â”‚
â”‚ â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”‚
â”‚ Binding Affinity Score: 0.94 / 1.00                                   â”‚
â”‚ Predicted IC50: 3.1 nM (Strong Binder)                                â”‚
â”‚ Confidence Level: 91%                                                  â”‚
â”‚                                                                         â”‚
â”‚ Against Predicted Mutation:                                            â”‚
â”‚   â€¢ Binding maintained: 89% effectiveness                              â”‚
â”‚   â€¢ Mutation resistance: Medium-High                                   â”‚
â”‚   â€¢ Recommended dosage: Standard + 10% boost                           â”‚
â”‚                                                                         â”‚
â”‚ â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”‚
â”‚ #2 Remdesivir          Score: 0.89  IC50: 100 nM    â­â­â­            â”‚
â”‚ #3 Molnupiravir        Score: 0.85  IC50: 500 nM    â­â­â­            â”‚
â”‚ #4 Favipiravir         Score: 0.78  IC50: 4.8 Î¼M    â­â­              â”‚
â”‚ #5 Sofosbuvir          Score: 0.62  IC50: 2.5 Î¼M    â­â­              â”‚
â”‚                                                                         â”‚
â”‚ [View Full Rankings] [Compare Drugs] [Export Results]                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ [5] 3D MOLECULAR VISUALIZATION                        [Interactive]   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                         â”‚
â”‚  â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•—         â”‚
â”‚  â•‘                                                           â•‘         â”‚
â”‚  â•‘        ğŸ”µ SARS-CoV-2 Spike Protein (6VXX)                â•‘         â”‚
â”‚  â•‘              â•±â•²                                           â•‘         â”‚
â”‚  â•‘             â•±  â•²    ğŸ”´ Binding Site                       â•‘         â”‚
â”‚  â•‘            â•±____â•²                                         â•‘         â”‚
â”‚  â•‘           â•±      â•²    âš¡ Nirmatrelvir                     â•‘         â”‚
â”‚  â•‘          â”‚ Proteinâ”‚     â”‚                                 â•‘         â”‚
â”‚  â•‘          â”‚________â”‚â”€â”€â”€â”€â”€â”¤ Drug                            â•‘         â”‚
â”‚  â•‘                         â”‚ Molecule                        â•‘         â”‚
â”‚  â•‘                                                           â•‘         â”‚
â”‚  â•‘  Binding Energy: -8.4 kcal/mol (Strong)                  â•‘         â”‚
â”‚  â•‘  H-Bonds Formed: 5                                        â•‘         â”‚
â”‚  â•‘  Hydrophobic Contacts: 12                                 â•‘         â”‚
â”‚  â•‘                                                           â•‘         â”‚
â”‚  â•‘  [Rotate] [Zoom] [Highlight Residues] [Play Animation]   â•‘         â”‚
â”‚  â•šâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•         â”‚
â”‚                                                                         â”‚
â”‚  Key Interactions:                                                     â”‚
â”‚    â€¢ Cys145 (catalytic) â†’ Drug carbonyl group (H-bond)                â”‚
â”‚    â€¢ His41 (catalytic) â†’ Drug amide (Ï€-Ï€ stacking)                    â”‚
â”‚    â€¢ Glu166 â†’ Drug NH group (Salt bridge)                             â”‚
â”‚                                                                         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ [6] AI-SUGGESTED CHEMICAL MODIFICATIONS                   ğŸ§ª OPTIMIZE â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Original Drug: Nirmatrelvir                                            â”‚
â”‚ Current IC50: 3.1 nM                                                   â”‚
â”‚                                                                         â”‚
â”‚ AI-RECOMMENDED MODIFICATIONS:                                          â”‚
â”‚                                                                         â”‚
â”‚ Modification #1: Add fluorine to Position 12               â­ TOP REC â”‚
â”‚ â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”‚
â”‚ Original Structure:                                                    â”‚
â”‚   -CHâ‚‚-CHâ‚ƒ (ethyl group at position 12)                               â”‚
â”‚                                                                         â”‚
â”‚ Modified Structure:                                                    â”‚
â”‚   -CHF-CHâ‚ƒ (fluoroethyl group)                                        â”‚
â”‚                                                                         â”‚
â”‚ Predicted Improvements:                                                â”‚
â”‚   â€¢ Binding affinity: +18% (est. IC50: 2.5 nM)                        â”‚
â”‚   â€¢ Metabolic stability: +23%                                          â”‚
â”‚   â€¢ Bioavailability: +15%                                              â”‚
â”‚   â€¢ Toxicity risk: -12% (improved safety profile)                     â”‚
â”‚                                                                         â”‚
â”‚ Confidence: 84%                                                        â”‚
â”‚ Synthetic Feasibility: High                                            â”‚
â”‚                                                                         â”‚
â”‚ â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”‚
â”‚ Modification #2: Methyl group addition to aromatic ring              â”‚
â”‚ â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”‚
â”‚ Predicted IC50: 2.8 nM (+12% improvement)                             â”‚
â”‚ Confidence: 79%                                                        â”‚
â”‚                                                                         â”‚
â”‚ â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”‚
â”‚ Modification #3: Hydroxyl substitution                               â”‚
â”‚ â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”‚
â”‚ Predicted IC50: 3.0 nM (+3% improvement)                              â”‚
â”‚ Confidence: 72%                                                        â”‚
â”‚                                                                         â”‚
â”‚ [View Modified Structures in 3D] [Export for Synthesis]               â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ [7] ACTIONABLE RECOMMENDATIONS                                         â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Based on complete analysis:                                            â”‚
â”‚                                                                         â”‚
â”‚ IMMEDIATE ACTIONS:                                                     â”‚
â”‚   1. âœ… Deploy Nirmatrelvir (Paxlovid) as first-line treatment        â”‚
â”‚   2. âš¡ Stock Remdesivir as backup option                              â”‚
â”‚   3. ğŸ”¬ Begin synthesis of Modified Nirmatrelvir (Mod #1)              â”‚
â”‚   4. ğŸ“Š Monitor mutation emergence in next 90 days                     â”‚
â”‚                                                                         â”‚
â”‚ RESEARCH PRIORITIES:                                                   â”‚
â”‚   â€¢ Conduct in-vitro testing of top 3 candidates                      â”‚
â”‚   â€¢ Validate modified drug structures                                  â”‚
â”‚   â€¢ Clinical trial preparation for new variant                         â”‚
â”‚                                                                         â”‚
â”‚ [Generate Full Report PDF] [Share with Team] [Export Data]            â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜